CFTR and cystic fibrosis: The introduction of VX-770 (ivacaftor, Kalydeco©) into clinical use for the treatment of cystic fibrosis (CF) was the first therapy targeting the underlying cause of the disease: the dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel.